ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of Acute Leukemia

Published: 5 March 2018| Version 1 | DOI: 10.17632/txwvx9t34b.1
Contributor:
tamara maes

Description

Experiment design THP-1 H3K4me2 ChIPSeq Data after ORY-1001 treatment

Files

Institutions

Oryzon

Categories

Epigenetics

Licence